Long-term Extension Study of Tolebrutinib in Multiple Sclerosis

Phase 3, open-label trial of tolebrutinib in multiple sclerosis (MS) (2 arms), sponsored by Sanofi. Primary endpoints: Number of Participants with Adverse Events, Serious Adverse Events, Adverse Events of Special Interest, and AEs leading to permanent study intervention discontinuation at 4 years and Number of Participants with Potentially Clinically Significant Abnormalities at 4 years. Started Apr 2024; status: active, not recruiting.